| Price, Francis W |
NCT05136443: Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection |
|
|
| Completed | 4 | 70 | US | loteprednol etabonate 0.25% ophthalmic suspension, Eysuvis | Price Vision Group, Kala Pharmaceuticals, Inc. | Corneal Endothelial Dystrophy, Corneal Edema | 09/23 | 09/23 | | |
| Recruiting | 4 | 44 | US, RoW | CT LUCIA 621P | Carl Zeiss Meditec AG | Cataract | 12/24 | 12/24 | | |
NCT05255107: Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers |
|
|
| Recruiting | 2/3 | 468 | US | Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution, Standard of Care Therapy + Sham CXL + Artificial Tears | Peschke GmbH | Keratitis, Corneal Ulcer | 11/23 | 02/24 | | |
NCT05255016: Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers |
|
|
| Recruiting | 2/3 | 488 | US | PXL Platinum 330 system + Riboflavin 0.25% TE Solution, Sham CXL + Artificial Tears | Peschke GmbH | Keratitis, Corneal Ulcer | 11/23 | 02/24 | | |
NCT04787471: Corneal Crosslinking for Treatment of Corneal Neovascularization |
|
|
| Recruiting | 2/3 | 62 | US | 30 minute photoactivation of riboflavin 0.1%, 10 minute photoactivation of riboflavin 0.1% | Price Vision Group, Cornea Research Foundation of America | Corneal Neovascularization | 07/25 | 09/25 | | |
NCT03922542: Comparison of Standard vs. Accelerated Corneal Crosslinking |
|
|
| Recruiting | 2/3 | 510 | US | riboflavin 0.1%, Riboflavin 0.1% | Price Vision Group | Keratoconus, Ectasia Corneal | 06/26 | 07/26 | | |
| Kay, Christine |
| Completed | 3 | 97 | Europe, Canada, US, RoW | Genetic: AAV5-hRKp.RPGR, botaretigene sparoparvovec | Janssen Research & Development, LLC, Janssen Research & Development, LLC | X-Linked Retinitis Pigmentosa | 09/24 | 09/24 | | |
| Active, not recruiting | 3 | 97 | Europe, Canada, US, RoW | Genetic: AAV5-hRKp.RPGR Intermediate Dose, botaretigene sparoparvovec, Genetic: AAV5-hRKp.RPGR Low Dose | Janssen Research & Development, LLC, Janssen Research & Development, LLC | X-Linked Retinitis Pigmentosa | 09/29 | 12/29 | | |
| Recruiting | 2 | 140 | US | ALK-001, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Placebo | Alkeus Pharmaceuticals, Inc. | Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related) | 12/24 | 03/25 | | |
| Recruiting | 1/2 | 215 | US | 4D-150 IVT, Aflibercept IVT | 4D Molecular Therapeutics | Neovascular (Wet) Age-Related Macular Degeneration | 11/25 | 11/26 | | |
| Rosa, Potyra |
| Terminated | 3 | 14 | Europe, US, RoW | Presendin, Placebo | Invex Therapeutics Ltd., Premier Research Group plc, University Hospitals Birmingham Neuro Ophthalmology Reading Centre, Birmingham, UK, Iowa Visual Field Reading Centre, Iowa, USA | Idiopathic Intracranial Hypertension | 09/23 | 10/23 | | |
| Lam, Byron |
| Terminated | 3 | 14 | Europe, US, RoW | Presendin, Placebo | Invex Therapeutics Ltd., Premier Research Group plc, University Hospitals Birmingham Neuro Ophthalmology Reading Centre, Birmingham, UK, Iowa Visual Field Reading Centre, Iowa, USA | Idiopathic Intracranial Hypertension | 09/23 | 10/23 | | |
| Recruiting | 3 | 150 | US | Sub-Retinal Administration of OCU400-301 | Ocugen | Retinitis Pigmentosa | 06/25 | 10/26 | | |
| Recruiting | 2 | 140 | US | ALK-001, C20-D3-Retinyl Acetate, C20 Deuterated vitamin A, Placebo | Alkeus Pharmaceuticals, Inc. | Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related) | 12/24 | 03/25 | | |
| Recruiting | 1/2 | 33 | Europe, US | SPVN06 | SparingVision | Retinitis Pigmentosa | 03/25 | 03/29 | | |
| Recruiting | 1/2 | 21 | US | ATSN-201 | Atsena Therapeutics Inc. | X-linked Retinoschisis | 10/25 | 10/29 | | |
| Recruiting | 1 | 20 | US | VP-001 | PYC Therapeutics | Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11 | 05/24 | 05/24 | | |
NCT06140329: Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation |
|
|
| Recruiting | N/A | 40 | Europe, US, RoW | | PYC Therapeutics | Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant, Optic Atrophies, Hereditary, Kjer Optic Atrophy | 03/26 | 06/26 | | |
POLARIS, NCT06435000: An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene |
|
|
| Recruiting | N/A | 75 | Europe, US | | Splice Bio | Stargardt, Stargardt's Disease, Stargardt Disease, STGD1 | 12/26 | 02/27 | | |
| Caldwell, Doris Ann |
| Active, not recruiting | 2 | 352 | Europe, Canada, US | tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin | Seagen Inc., Genmab, Merck Sharp & Dohme LLC | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck | 02/26 | 11/26 | | |
